1. EPA for prevention and treatment of bowel cancer Professor Mark Hull Leeds Institute of Biomedical & Clinical Sciences University of Leeds and Leeds Teaching Hospitals…

Author Proof Advanced Review Understanding drug-likeness Oleg Ursu,1,2 Anwar Rayan,3,4 Amiram Goldblum3 and Tudor I. Oprea1,2∗ ‘Drug-likeness’, a qualitative property…

Slide 1Decoding the Network Footprint of Diseases With increasing availability of data, there is significant activity directed towards correlating genomic, proteomic, metabolomic,…

Slide 1 Slide 2 Background Goals Methods Results Conclusions Implications Slide 3 Proteins – organic compounds that constitute the basic functional and computational unit…

What Really Happens When I Take a Drug? Philip E. Bourne University of California San Diego [email protected] http://www.sdsc.edu/pb Vancouver April 12, 2012 Big Questions…

Slide 1 Decoding the Network Footprint of Diseases With increasing availability of data, there is significant activity directed towards correlating genomic, proteomic, metabolomic,…

ON A HIGH AT ERBI'S BENCH2BOARDROOM ERBI CEO Harriet Fear explained that the objective had been to create an enabling environment for the sector to do business. âThe…

Slide 1 Sparse-matrix analysis of small molecules and protein targets for drug discovery Gerald J. Wyckoff, UMKC What drives our research? The pharmaceutical industry is…

Hutchinson-Gilford progeria syndrome_ Rejuvenating old drugs to fight accelerated ageingSubmitted on 20 Apr 2020 HAL is a multi-disciplinary open access archive for the deposit